Shanghai Yizhong Pharma’s YXC‑001 Phase‑I Success Signals Potential Upside Despite Flat Market
Shanghai Yizhong Pharmaceutical’s YXC‑001 phase‑I success hints at a promising multi‑modal oncology platform, yet market volatility and regulatory uncertainty temper current stock performance.
3 minutes to read